| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Glycopyrronium bromide |
| Brand | Sialanar® |
| Indication | For symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. |
| Assessment Process | |
| Rapid review commissioned | 07/03/2017 |
| Rapid review completed | 13/04/2017 |
| Rapid review outcome | A full HTA is recommended at the submitted price. |
Updated June 2017
Following an update to the rapid review of Glycopyrronium bromide (Sialanar®), a full pharmacoeconomic assessment is not recommended.